All In Biotech

Drug Trial Radar · NCT07729956

A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)

A Phase III Randomized Controlled Clinical Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 436 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

436

Planned (sponsor's estimate)

Start

Sep 2, 2026

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Sponsor type
Industry
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
Jul 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a registrational Phase III, randomized, open-label, multicenter study designed to compare the efficacy and safety of BL-B01D1 in combination with a PD-1 monoclonal antibody versus nab-paclitaxel in combination with a PD-1 monoclonal antibody in patients with PD-L1-positive, previously untreated, inoperable locally advanced or recurrent metastatic triple-negative breast cancer.

Conditions

  • Triple-Negative Breast Cancer (TNBC)

Interventions

  • BL-B01D1Drug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • PD-1 monoclonal antibodyDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • Nab-paclitaxelDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BICR-assessed Progression-free Survival (PFS)Time frame: Up to approximately 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.